The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.21 million delivery order to the University of Nebraska Medical Center (UNMC) on August 1, 2024, for preclinical services supporting HIV therapeutics research. The specific focus is pharmacokinetic/pharmacodynamic (PK/PD) evaluation and assessment of T-5224's effect on HIV-1 transcriptional activity using an HIV-1-mouse model. This delivery order is issued under the "Preclinical Services for HIV Therapeutics" master indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The work will be performed in Omaha, Nebraska, with an ultimate completion date of November 30, 2026. No small business set-aside designation applies to this contract, and it is structured as a cost-plus-no-fee arrangement, indicating reimbursement of allowable costs without profit markup.
UNMC, operating under the Board of Regents of the University of Nebraska, is well-positioned to execute this award given its extensive experience conducting biomedical research and drug development support services for federal agencies. The institution maintains substantial grant funding from NIAID and other National Institutes of Health components for HIV-related research, including recent awards for pediatric HIV formulation development. UNMC's demonstrated capabilities across infectious disease research, preclinical laboratory services, and animal model studies align directly with the contract requirements for evaluating novel HIV therapeutic candidates through rigorous pharmacological and virological assessments.